[1]刘明波, 何新叶, 杨晓红, 等. 《中国心血管健康与疾病报告2023》要点解读[J]. 中国心血管杂志, 2024, 29(4): 305-324.
[2]Reynolds H R, Shaw L J, Min J K, et al. Outcomes in the ISCHEMIA trial based on coronary artery disease and ischemia severity[J]. Circulation, 2021, 144(13): 1024-1038.
[3]Min J K, Dunning A, Lin F Y, et al. Age-and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings results from the international multicenter CONFIRM (coronary CT angiography evaluation for clinical outcomes: an international multicenter registry) of 23 854 patients without known coronary artery disease[J]. J Am Coll Cardiol, 2011, 58(8): 849-860.
[4]Lopes N H, Paulitsch Fda S, Gois A F, et al. Impact of number of vessels disease on outcome of patients with stable coronary artery disease: 5-year follow-up of the medical, angioplasty, and bypass surgery study (MASS)[J]. Eur J Cardiothorac Surg, 2008, 33(3): 349-354.
[5]Liu Z P, Li J P, Zhang Y, et al. Trends in percutaneous coronary intervention in China: analysis of China PCI registry data from 2010 to 2018[J]. Cardiology Plus, 2022, 7: 118-124.
[6]Makris K, Spanou L. Is there a relationship between mean blood glucose and glycated hemoglobin?[J]. J Diabetes Sci Technol, 2011, 5(6): 1572-1583.
[7]Hong L F, Li X L, Guo Y L, et al. Glycosylated hemoglobin A1c as a marker predicting the severity of coronary artery disease and early outcome in patients with stable angina[J]. Lipids Health Dis, 2014, 13: 89.
[8]Alber H F, Wanitschek M M, De Waha S, et al. High-density lipoprotein cholesterol, C-reactive protein, and prevalence and severity of coronary artery disease in 5641 consecutive patients undergoing coronary angiography[J]. Eur J Clin Invest, 2008, 38(6): 372-380.
[9]Parhofer K G. Interaction between glucose and lipid metabolism: more than diabetic dyslipidemia[J]. Diabetes Metab J, 2015, 39(5): 353-362.
[10]Hu X M, Li W, Wang C Y, et al. Association between the plasma-glycosylated hemoglobin A1c/high-density lipoprotein cholesterol ratio and carotid atherosclerosis: a retrospective study[J]. J Diabetes Res, 2021, 2021: 9238566.
[11]Gui M H, Qin G Y, Ning G, et al. The comparison of coronary angiographic profiles between diabetic and nondiabetic patients with coronary artery disease in a Chinese population[J]. Diabetes Res Clin Pract, 2009, 85(2): 213-219.
[12]Garg N, Moorthy N, Kapoor A, et al. Hemoglobin A1c in nondiabetic patients: an independent predictor of coronary artery disease and its severity[J]. Mayo Clin Proc, 2014, 89(7): 908-916.
[13]Jiao X J, Zhang Q, Peng P, et al. HbA1c is a predictive factor of severe coronary stenosis and major adverse cardiovascular events in patients with both type 2 diabetes and coronary heart disease[J]. Diabetol Metab Syndr, 2023, 15(1): 50.
[14]Won K B, Lee B K, Lin F Y, et al. Glycemic control is independently associated with rapid progression of coronary atherosclerosis in the absence of a baseline coronary plaque burden: a retrospective case-control study from the PARADIGM registry[J]. Cardiovasc Diabetol, 2022, 21(1): 239.
[15]Dykun I, Bayturan O, Carlo J, et al. HbA1c, coronary atheroma progression and cardiovascular outcomes[J]. Am J Prev Cardiol, 2022, 9: 100317.
[16]Cheng Y, Zou J, Chu R, et al. Cumulative HbA1c exposure as a CVD risk in patients with type 2 diabetes: a post hoc analysis of ACCORD trial[J]. Diabetes Res Clin Pract, 2023, 206: 111009.
[17]Huang D, Huang Y Q, Zhang Q Y, et al. Association between long-term visit-to-visit hemoglobin A1c and cardiovascular risk in type 2 diabetes: the ACCORD trial[J]. Front Cardiovasc Med, 2021, 8: 777233.
[18]Jia G, Bai H, Mather B, et al. Diabetic vasculopathy: molecular mechanisms and clinical insights[J]. Int J Mol Sci, 2024, 25(2): 804.
[19]Biddinger S B, Hernandez-Ono A, Rask-Madsen C, et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis[J]. Cell Metab, 2008, 7(2): 125-134.
[20]Poznyak A, Grechko A V, Poggio P, et al. The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation[J]. Int J Mol Sci, 2020, 21(5): 1835.
[21]Hoofnagle A N, Vaisar T, Mitra P, et al. HDL lipids and insulin resistance[J]. Curr Diab Rep, 2010, 10(1): 78-86.
[22]Li N S, Fu J Y, Koonen D P, et al. Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance?[J]. Atherosclerosis, 2014, 233(1): 130-138.
[23]Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease[J]. JAMA, 2009, 302(18): 1993-2000.
[24]Wang Y, Yan T, Yang Y X, et al. Association between changes in high-density lipoprotein cholesterol and risk of cardiovascular disease[J]. J Clin Lipidol, 2024, 18(6): e1025-e1034.
[25]Ballantyne C M, Herd J A, Ferlic L L, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy[J]. Circulation, 1999, 99(6): 736-743.
[26]Liu H H, Guo Y L, Wu N Q, et al. High-density lipoprotein cholesterol levels are associated with coronary severity but not with outcomes in new-onset patients with stable coronary artery disease[J]. Atherosclerosis, 2017, 263: 104-111.
[27]Yang H S, Jeong H J, Kim H, et al. Sex-specific U-shaped relationships between high-density lipoprotein cholesterol levels and 10-year major adverse cardiovascular events: a nationwide cohort study of 5.7 million South Koreans[J]. Ann Lab Med, 2022, 42(4): 415-427.
[28]Lui D T W, Li L L, Liu X D, et al. The association of HDL-cholesterol levels with incident major adverse cardiovascular events and mortality in 0.6 million individuals with type 2 diabetes: a population-based retrospective cohort study[J]. BMC Med, 2024, 22(1): 586.
[29]Endo Y, Fujita M, Ikewaki K. HDL Functions-current status and future perspectives[J]. Biomolecules, 2023, 13(1): 105.
[30]Mete M, Wilson C, Lee E T, et al. Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience[J]. J Diabetes Complications, 2011, 25(6): 362-367.
[31]Zhang X D, Van Der Vorst E P C. High-density lipoprotein modifications: causes and functional consequences in type 2 diabetes mellitus[J]. Cells, 2024, 13(13): 1113.
[32]Abbasi A, Corpeleijn E, Gansevoort R T, et al. Role of HDL cholesterol and estimates of HDL particle composition in future development of type 2 diabetes in the general population: the PREVEND study[J]. J Clin Endocrinol Metab, 2013, 98(8): E1352-E1359.
[33]Lee S H, Kim H S, Park Y M, et al. HDL-cholesterol, its variability, and the risk of diabetes: a nationwide population-based study[J]. J Clin Endocrinol Metab, 2019, 104(11): 5633-5641.
[34]He S M, Lu S, Yu C H, et al. The newly proposed plasma-glycosylated hemoglobin A1c/high-density lipoprotein cholesterol ratio serves as a simple and practical indicator for screening metabolic associated fatty liver disease: an observational study based on a physical examination population[J]. BMC Gastroenterol, 2024, 24(1): 274.
[35]Huang C J, You H T, Zhang Y Y, et al. Association between the hemoglobin A1c/high-density lipoprotein cholesterol ratio and stroke incidence: a prospective nationwide cohort study in China[J]. Lipids Health Dis, 2025, 24(1): 25.
[36]Sun F, Yu X J, Huang X H, et al. The association between glycated hemoglobin to high density lipoprotein cholesterol ratio and risk of cardiovascular diseases caused death among adult cancer survivors: evidence from NHANES 1999-2018[J]. Lipids Health Dis, 2025, 24(1): 149.
|